Ardelyx (ARDX) Jumps 9.57% After-Hours on Q3 Earnings Beat, Reaffirmed Guidance

Ardelyx (ARDX) shares surged 9.57% in after-hours trading following its Q3 2026 earnings report. The biotech company reported a 19% year-over-year revenue increase and a narrowed net loss, moving closer to profitability. While product revenue of $125.5 million slightly missed the $129.22 million forecast, investors focused on strong demand for IBSRELA and reaffirmed full-year guidance. The company ended the quarter with $285.3 million in cash, indicating strong financial health as it scales operations [1].